The UK accounts for more than a quarter of all European entrepreneural biosciences companies and over 90% of publicly-quoted bioscience firms in Europe, according to a new study published last month by Ernst & Young.
The report is a supplement to Ernst & Young's well-respected European Biotech '96 report, the third in the series, which was published in April. Key findings of the new study are summarized here.
Ernst & Young estimates that the total turnover of entrepreneurial UK bioscience firms currently stands at L310 million ($478.6 million), which is a 25% increase on the previous year. This level of turn-over accounts for 32% of the total European sector, and the firm anticipates that this will increase over the next few years as UK companies begin to build their revenues. By March 1996, the market capitalization of the publicly-quoted UK firms had topped L5 billion, and is still rising.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze